Literature DB >> 11675067

Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.

W Jessner, M Gschwantler, P Steindl-Munda, H Hofer, T Watkins-Riedel, F Wrba, C Mueller, A Gangl, P Ferenci.   

Abstract

Only 30% of patients with chronic hepatitis C virus genotype 1 (HCV-1) infection achieve a sustained virological response to interferon and ribavirin combination therapy. We prospectively assessed decline in viral load 24 h after one dose of interferon alfa as a predictor of non-response to 6 months of treatment with interferon and ribavirin. Interferon sensitivity was measured before initiation of combination therapy. We measured viral load in 29 consecutive patients, who had not previously been treated with interferon and who were chronically infected with HCV-1 within 24 h after one dose of 5 MU or 10 MU interferon alfa-2b, and 14 days of daily 5 MU interferon alfa-2b. A 24 h viral load decline by less than 70% of baseline after 5 MU interferon was the best pretreatment measure to identify non-responders (specificity 100%, n=10, 95% CI 74-100], sensitivity 83% [15/18], 59-96]).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675067     DOI: 10.1016/S0140-6736(01)06356-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

1.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

Review 2.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

3.  Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle.

Authors:  Chloe L Thio; David L Thomas
Journal:  Gastroenterology       Date:  2010-02-23       Impact factor: 22.682

4.  Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.

Authors:  Masahiko Takahashi; Hidetsugu Saito; Makiko Higashimoto; Kazuhiro Atsukawa; Hiromasa Ishii
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Ribavirin improves early responses to peginterferon through improved interferon signaling.

Authors:  Jordan J Feld; Glen A Lutchman; Theo Heller; Koji Hara; Julie K Pfeiffer; Richard D Leff; Claudia Meek; Maria Rivera; Myung Ko; Christopher Koh; Yaron Rotman; Marc G Ghany; Vanessa Haynes-Williams; Avidan U Neumann; T Jake Liang; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2010-03-17       Impact factor: 22.682

6.  Hepatitis C Viral Kinetics in Special Populations.

Authors:  Harel Dahari; Jennifer E Layden-Almer; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2008

7.  Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.

Authors:  Hakan Senturk; Galip Ersoz; Resat Ozaras; Sabahattin Kaymakoglu; Hakan Bozkaya; Meral Akdogan; Ali Mert; Mithat Bozdayi; Fehmi Tabak; Necati Yenice; Gulsen Ozbay
Journal:  Dig Dis Sci       Date:  2003-06       Impact factor: 3.199

8.  Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.

Authors:  Magnus Lindh; Erik Alestig; Birgitta Arnholm; Anders Eilard; Kristoffer Hellstrand; Martin Lagging; Thomas Wahlberg; Rune Wejstål; Johan Westin; Gunnar Norkrans
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

9.  Current Treatment for Chronic Hepatitis C.

Authors:  Peter Ferenci
Journal:  Curr Treat Options Gastroenterol       Date:  2004-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.